Skip to main content

Advertisement

Table 1 Efficacy results by group and dose level (per protocol analysis)

From: Methylene blue for malaria in Africa: results from a dose-finding study in combination with chloroquine

  2× daily 4× daily Group comparison
Level1 MB 36 mg/kg
- ETF/N 1.6%, 1/62 3.0%, 2/66 p = 0.5923 (1)
- LCF14/N 8.1%, 5/62 3.0%, 2/66 p = 0.2047 (1)
- TF14/N 9.7%, 6/62 6.1%, 4/66 p = 0.4452 (1)
- LPF14/N 24.2%, 15/62 22.7%, 15/66 p = 0.8449 (1)
Level2 MB 54 mg/kg
- ETF/N 3.1%, 2/64 6.9%, 5/73 p = 0.3140 (1)
- LCF14/N 4.7%, 3/64 11.0%, 8/73 p = 0.1688 (1)
- TF14/N 7.8%, 5/64 17.8%, 13/73 p = 0.0783 (1)
- LPF14/N 35.9%, 23/64 17.8%, 13/73 p = 0.0159 (1)
Level3 MB 72 mg/kg
- ETF/N 0.0%, 0/47 0.0%, 0/52 -
- LCF14/N 10.6%, 5/47 9.6%, 5/52 p = 0.8661 (1)
- TF14/N 10.6%, 5/47 9.6%, 5/52 p = 0.8661 (1)
- LPF14/N 21.3%, 10/47 19.2%, 10/52 p = 0.8002 (1)
Level comparison
- p-value (ETF) 0.3266 (2) 0.0595 (2) 0.7290 (3), 0.0960 (4), 0.9930 (5)
- p-value (LCF14) 0.4824 (2) 0.1492 (2) 0.3168 (3), 0.2613 (4), 0.1722 (5)
- p-value (LF14) 0.8684 (2) 0.0838 (2) 0.2944 (3), 0.2634 (4), 0.1984 (5)
- p-value (LPF14) 0.1764 (2) 0.7631 (2) 0.1155 (3), 0.4045 (4), 0.2486 (5)
  1. ETF = early treatment failure, LCF14 = late clinical failure (day 14), TF14 = treatment failure (ETF or LCF14), LPF14 = late parasitological failure (day 14), (1) group comparisons within level, (2) level comparison within group, (3) test of overall group comparison, (4) test of overall level comparison, (5) test of group*level interaction, Likelihood ratio tests were used